dcsimg Aranesp® (darbepoetin alfa) – Efficacy for Patients on Dialysis
› Email› Print

Aranesp® effectively maintained mean Hb levels for patients on dialysis1

Aranesp® effectively maintained mean Hb levels for patients on dialysis

Mean Hb levels were maintained with Aranesp® QW and Q2W dosing1,2

Mean Hb levels were maintained with QW and Q2W dosing

Important Safety Information

  • Serious allergic reactions, including anaphylactic reactions, angioedema, bronchospasm, skin rash, and urticaria may occur with Aranesp®. Immediately and permanently discontinue Aranesp® if a serious allergic reaction occurs.
  • Adverse reactions (≥ 10%) in Aranesp® clinical studies in patients with CKD were hypertension, dyspnea, peripheral edema, cough, and procedural hypotension.

Scroll down for additional
Important Safety Information.

Abbreviations and References:
BIW = twice weekly; CKD = chronic kidney disease; Hb = hemoglobin; mITT = modified intent-to-treat patients enrolled in the study and received at least 1 dose of study drug; QW = once weekly; Q2W = once every 2 weeks; TIW = three times weekly.
References: 1. Vanrenterghem Y, Bárány P, Mann JFE, et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int. 2002;62:2167-2175. 2. Nissenson AR, Swan SK, Lindberg JS, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis. 2002;40:110-118.

Biotechnology by Amgen®